The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]: Guidance for Industry and Food and Drug Administration Staff
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 28, 2014
March 28, 2019
b5031711-1d58-4c45-b081-f570f50bba71
Related Documents
Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics: Guidance for Industry and Food and Drug Administration Staff
Guidance DocumentSeptember 25, 2018Center for Devices and Radiological Health
Types of Communication During the Review of Medical Device Submissions: Guidance for Industry and FDA Staff
Guidance DocumentApril 4, 2014Center for Devices and Radiological Health
FDA Decisions for Investigational Device Exemption Clinical Investigations: Guidance for Sponsors, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff
Guidance DocumentAugust 19, 2014Center for Devices and Radiological Health
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.